Lutris Pharma Completes Enrollment in Phase 2 Trial of LUT014 for the Treatment of EGFRI-Induced Acneiform Rash in Patients with Metastatic Colorectal Cancer

Lutris Pharma Israel United Kingdom

View original content:https://www.prnewswire.co.uk/news-releases/lutris-pharma-completes-enrollment-in-phase-2-trial-of-lut014-for-the-treatment-of-egfri-induced-acneiform-rash-in-patients-with-metastatic-colorectal-cancer-302275406.html